Remibrutinib is an oral BTK inhibitor currently being investigated in a phase 2 trial in urticaria. It was a pleasure to talk with Prof. Ana Maria Giménez-Arnau (Hospital del Mar. IMIM, Universitat Autònoma de Barcelona, Barcelona, Spain) around the safety findings from the long term extension of a phase 2b study of remibrutinib in chronic spontaneous urticaria patients.
The abstract ‘Long-term safety and tolerability of remibrutinib (LOU064) in Phase 2b study in chronic spontaneous urticaria patients.’ was presented at EAACI 2022, 1-3 July, 2022.
Questions
- What were the aims, design and eligibility criteria of the phase 2b study? (0:35)
- What were the safety findings of the study? (2:18)
- What makes this therapy so attractive compared to other treatment modalities for CSU? (8:38)
Disclosures: Ana Maria Giménez-Arnau discloses consulting for Novartis; receiving grant/ research support from Novartis; serving on advisory boards for Novartis; and receiving honoraria from Novartis.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the EAACI Hybrid Congress 2022.
